𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours

✍ Scribed by M. Schiesser; P. Veit-Haibach; M. K. Muller; M. Weber; P. Bauerfeind; T. Hany; P.-A. Clavien


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
220 KB
Volume
97
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Functional imaging of neuroendocrine tum
✍ Irfan Kayani; Jamshed B. Bomanji; Ashley Groves; Gerard Conway; Sveto Gacinovic; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 252 KB

## Abstract ## BACKGROUND. The aim was to assess the relevant distribution of the novel PET tracer ^68^Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission tomography / computed tomography (PET/CT) and compare its performance with that of ^18^F‐FDG PET/CT. ## METHODS. The

Radiosynthesis of 6-([18F]fluoroacetamid
✍ Uday Mukhopadhyay; William P. Tong; Juri G. Gelovani; Mian M. Alauddin πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 290 KB

## Abstract Radiosynthesis of a novel substrate for histone deacetylase (HDAC), 6‐([^18^F]fluoroacetamido)‐1‐hexanoicanilide ([^18^F]FAHA, [^18^F]‐**3**) is reported. For precursor synthesis, compound **1** (6‐amino‐1‐hexanoicanilide) was prepared by the reaction of 6‐amino hexanoic acid with thion

The synthesis of a new probe for PET ima
✍ Hancheng Cai; Duanzhi Yin; Lan Zhang; Yongxian Wang πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 199 KB

The one step radiosynthesis of 2-amino-6-[ 18 F]fluoro-9-(4-hydroxy-3-hydroxymethylbutyl) purine (6-[ 18 F]fluoropenciclovir) 6 is reported. Radiolabeled product 6-[ 18 F]fluoropenciclovir 6 was prepared by radiofluorination of compound 4 with [ 18 F]KF and isolated by a silica Sep-Pak cartridge. Th

Fluorine-18 labeling of 6,7-disubstitute
✍ Yann Seimbille; Michael E. Phelps; Johannes Czernin; Daniel H. S. Silverman πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 157 KB

Inhibitors of tyrosine kinase enzymatic activity represent a promising new class of antineoplastic agents. Although clinical studies performed over the last decade give more insight on the potential therapeutic applications of such drugs, identification of the individual patients who might benefit f